On Individual Preferences and Aggregation in Economic Evaluation in Healthcare Bengt LiljasBjörn Lindgren Leading Article 23 September 2012 Pages: 323 - 335
Pharmacoeconomics of Hypertension Management Ettore Ambrosioni Review Article 23 September 2012 Pages: 337 - 347
Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies Anne M. RentzCarmelina BattistaDennis A. Revicki Review Article 23 September 2012 Pages: 349 - 363
Augmenting Reference Pricing of Pharmaceuticals in New Zealand with Strategic Cross-Product Agreements Alan Woodfield Review Article 23 September 2012 Pages: 365 - 377
The Cost of Treatment of Alzheimer’s Disease in The Netherlands Joseph McDonnellW. Ken RedekopFrans F. H. Rutten Original Research Article 23 September 2012 Pages: 379 - 390
Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines M. Rhona M. T. LimcangcoCarol L. ArmourSusan J. Taylor Original Research Article 23 September 2012 Pages: 391 - 400
Cost Effectiveness of Continuous Terbinafine Compared with Intermittent Itraconazole in the Treatment of Dermatophyte Toenail Onychomycosis Ronald JansenW. Ken RedekopFrans F. H. Rutten Original Research Article 23 September 2012 Pages: 401 - 410
Cost-Effectiveness Analysis of n-3 Polyunsaturated Fatty Acids (PUFA) after Myocardial Infarction Maria Grazia FranzosiMassimo BrunettiFranco Valagussa Original Research Article 23 September 2012 Pages: 411 - 420
Efavirenz Greg L. PloskerCaroline M. PerryKaren L. Goa Adis Pharmacoeconomic Drug Evaluation 23 September 2012 Pages: 421 - 436